Charles Payne here with an urgent opportunity:
The market just handed options traders a gift—and most people won't even notice it.
Volatility is spiking.
And when that happens, option premiums surge.
Options traders love it.
And so do I!
Because while everyone else is watching their portfolios swing wildly and losing sleep over whether to sell, options traders are cashing in on the chaos.
Higher volatility = fatter premiums = BIGGER paychecks.
You can collect more income in one volatile week than you'd normally make in a month of calm markets.
The opportunities right now are exceptional. But they won't last forever.
Volatility always settles down—and when it does, these premium levels disappear.
That’s why, in a few days, my team is hosting a free, live Power of Options Masterclass where we’re showing you exactly how to capitalize on these high-premium environments and what to do when the market gets cold.
You’ll learn how to collect significantly larger income checks. How to do it safely.
And how to take advantage before this window closes.
This is a live session. No charge.
The full details are on the next page…
So register here while the doors are open.
Charles Payne
2 Stocks With Governmental Tailwinds to Drive Them Higher
Written by Thomas Hughes. Originally Published: 3/17/2026.
Key Points
- Ondas and Amprius are positioning for greater defense-market access, with compliance milestones and procurement pathways as key 2026 catalysts.
- Ondas is framed as an early-stage growth story tied to drones and secure networking, with sentiment supported by rising coverage and improving institutional activity.
- Amprius is pitched as a defense battery enabler, with scaling execution and margin trajectory as the key swing factors alongside elevated short interest.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
A little government exposure can go a long way for a business, especially those still in early stages. Government spending—specifically defense—accounts for roughly 3% of GDP, making it a lucrative market. While headwinds remain, Ondas Inc. (NASDAQ: ONDS) and Amprius Technologies (NYSE: AMPX) are positioned to gain greater access to that market, giving them the potential for meaningful stock price appreciation in 2026. Over the longer term, rising defense spending supports a constructive outlook for the sector and these companies.
Ondas Inc. Expands Exposure, Set to Accelerate in 2026
Ondas is well positioned across two businesses: drone systems and private wireless networks. Its drone division manufactures easy-to-deploy "drone-in-a-box" systems and the software to operate them. The network business provides secure, private wireless solutions for government and industrial customers, helping bridge legacy infrastructure to modern data needs.
Former White House Insider Predicts New Gold Surge (Ad)
Analyst Jim Rickards believes gold could climb to $10,000 per ounce or higher in the coming years - and he says investors still have time to position ahead of the move.
His top recommendation is a $2 stock he describes as sitting on the largest gold deposit in the world, with an extraction green light potentially arriving April 15.
See Jim Rickards' number one gold recommendation for 2026Drivers in 2026 include several catalysts, such as Prime Contractor status for border security and placement on the Defense Contract Management Agency (DCMA) BLUE UAS Cleared list—both of which enable more rapid, strategic procurement of its drone and counter-drone technologies. Advantages include platform versatility and interchangeable hardware, plus automated kinetic counter-drone capability.
The earnings outlook is notable: the company is forecast to grow revenue by more than 570% this year, and estimates may be conservative. Longer-term forecasts also look robust, with growth expected to decelerate to about 260% in 2027 and again the following year. The balance sheet shows no obvious red flags—Ondas is well-capitalized with low leverage—so the company could outperform current forecasts and sustain a positive revision cycle in the quarters ahead.
Analyst and institutional trends are constructive. Analyst coverage is modest (eight analysts) but has increased roughly 300% over the trailing 12 months, providing growing conviction; the consensus rating is Moderate Buy, with price targets rising in early 2026 and upside of more than 50% at the high end. Institutions also show improving support: MarketBeat data indicate they own 37% of the stock and have been net buyers at about a 7-to-1 ratio for three consecutive quarters, reaching a historic high in Q1 2026.
Amprius Powering U.S. Defense Applications
Amprius has spent the past year improving compliance with the National Defense Authorization Act, which emphasizes secure domestic supply chains for defense applications. Amprius' batteries are well suited to meet those requirements.
The company's SiCore batteries deliver superior energy density, enabling larger payloads and longer ranges—useful for unmanned vehicles, man-portable systems, and a wide range of drones. Its technology has been validated by the DCMA and the Defense Innovation Unit (DIU), signaling growing adoption across defense applications.
Amprius' growth is expected to slow in 2026 but remain robust—above 70%—and to sustain a similar pace over the next three to five years. More importantly, the company is projected to reach profitability by the end of 2026 and to improve margins thereafter. The balance sheet looks solid in 2026, with a net cash position relative to total liabilities and no obvious red flags. The primary catalysts and risks next year will be scaling production and execution; if AMPX can scale with demand, the stock is likely to continue rising.
Analyst trends are supportive. A 2026 guidance update prompted six price target increases, moving consensus targets into the $20–$21 range; continued upgrades could push the stock back toward post-IPO highs just above $26. Institutional investors are net buyers but currently own only about 5% of the float, so they are not yet a dominant force. Meanwhile, short interest remains elevated (around 16% as of early March), a factor that has influenced the stock's price action.
Bottom line: Both Ondas and Amprius stand to benefit from increased government defense spending and procurement programs in 2026. Each faces execution risks, but their recent regulatory approvals, improving analyst coverage, and supportive institutional trends position them as names to watch if defense tailwinds continue.
Eli Lilly's Employer Push Could Unlock New GLP-1 Demand
By Leo Miller. First Published: 3/15/2026.
Key Points
- Eli Lilly is opening up a new way for employers to cover their weight-loss drugs.
- With half or more of employees not having coverage for obesity medications, Employer Connect could unlock significant demand for LLY.
- Meanwhile, the company's oral GLP-1 just beat out Novo's in a head-to-head type 2 diabetes duel.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
The world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), continues to assert its dominance in the weight-loss and diabetes drug markets in 2026.
In its most recent earnings report, the company forecast robust 25% growth for the year, well above expectations. While that would be much slower than the 45% growth Lilly generated in 2025, it would still mark the company’s third-highest annual growth rate in its history. Lilly’s current GLP-1 franchises should continue to drive strong sales increases, but growth can’t remain at sky-high rates forever.
Former White House Insider Predicts New Gold Surge (Ad)
Analyst Jim Rickards believes gold could climb to $10,000 per ounce or higher in the coming years - and he says investors still have time to position ahead of the move.
His top recommendation is a $2 stock he describes as sitting on the largest gold deposit in the world, with an extraction green light potentially arriving April 15.
See Jim Rickards' number one gold recommendation for 2026At the same time, Lilly’s top competitor, Novo Nordisk A/S (NYSE: NVO), is forecasting its weakest revenue growth in years. In 2026, Novo expects sales to decline between 5% and 13%. When measured in U.S. dollars, the company hasn’t seen a revenue drop of more than 5% since 2014; measured in Danish kroner, it hasn’t experienced such a decline since 1998.
This gap underscores Lilly’s stronger position, particularly in the market for currently available injectable GLP-1s.
Meanwhile, the healthcare company is taking steps to bolster its lead. Expanding drug access and winning the oral GLP-1 market are two key levers Lilly is working to pull.
Employer Connect: Lilly’s Bid to Crack the Huge Employer Coverage Gap
One of Lilly’s most significant recent moves is the launch of its Employer Connect platform, aimed at closing the gap in employer-sponsored obesity care. Lilly says roughly half of people on employer-sponsored plans lack coverage for obesity treatments. One survey found that just 20% of companies with more than 200 employees cover weight-loss drugs, and only 43% of firms with 5,000 employees or more do so.
That is a significant untapped opportunity. If employers don’t cover these drugs, patients must pay out of pocket. Through LillyDirect, the company’s direct-to-consumer platform, Zepbound costs about $299 to $449 per month. At those prices, many potential patients are likely priced out of treatment.
To address this, Lilly is offering Zepbound to employers at a discounted price of $449 per month, with employees responsible for only a small fraction of that cost. That is less than half of the drug’s list price of over $1,000. Employer Connect also bypasses traditional pharmacy benefit managers (PBMs), who act as intermediaries between drugmakers and insurers and often use opaque pricing agreements. The PBM industry is highly concentrated, giving those firms substantial negotiating leverage.
Through Employer Connect, employers can choose from more than 15 independent program administrators, allowing them to pick the option that best fits their needs. Lilly expects those administrators to compete with one another on services and price.
If employers adopt the program, Lilly could add significant Zepbound sales to its top line. However, meaningful contribution may not arrive until 2027, as employers evaluate and implement the new option.
There is some risk: if employers that already cover Zepbound switch to Employer Connect, Lilly could face lower per-unit pricing. Still, given the large coverage gap, the company appears willing to accept lower prices in exchange for much higher volume.
Lilly Scores Win in Smaller Oral Type 2 Diabetes Market
Lilly also reported positive results for its experimental oral GLP-1, orforglipron. In a head-to-head trial against Novo’s oral semaglutide (marketed as Rybelsus for type 2 diabetes), orforglipron produced superior blood-sugar reductions and greater weight loss.
A1C, a key marker of blood sugar control, fell by 2.2% for patients on orforglipron versus 1.4% for those on oral semaglutide. Weight loss averaged 9.2% with orforglipron compared with 5.3% for oral semaglutide.
Those results are encouraging as Lilly seeks approval of orforglipron for type 2 diabetes. Still, the oral diabetes market is relatively small compared with the broader GLP-1 market: Novo’s Rybelsus generated roughly $3.5 billion in sales in 2025, compared with about $32.5 billion in combined Ozempic and Wegovy sales at Novo the same year. Lilly is also pursuing approval of orforglipron as an oral obesity medication, which would represent a much larger opportunity.
LLY Keeps Opening New Doors to Drive Potential Growth
Overall, Lilly is expanding access and developing new products to broaden its customer base. While the company has already grown into an industry giant, its track record of execution and ongoing innovation make it a difficult stock to bet against.
to bring you the latest market-moving news.
This email message is a sponsored email for Paradigm Direct, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport. All rights reserved.
345 North Reid Place #620, Sioux Falls, S.D. 57103. United States..
0 Response to "The market just handed you a gift"
Post a Comment